Totality Of ‘Breakthrough’ Evidence Guides FDA Designation Decisions

Sponsors should think about more than just a single efficacy data point when assembling their designation requests because the agency looks at the ‘entire puzzle’ in deciding whether ‘breakthrough’ status is warranted.